pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL
Madrigal Pharmaceuticals EU
Madrigal Pharmaceuticals EU Limited
Madrigal Pharmaceuticals EU trial registry — 19 ClinicalTrials.gov studies with program phase, status, and indication context.
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US HQ
2016 Founded
1,071 Employees
Public company Type
MDGL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
- Founded
- 2016
- Employees
- 1,071
- Programs
- 16
- Drugs
- 11
- Patents
- 26
Madrigal Pharmaceuticals EU clinical trials
Registry index of 19 ClinicalTrials.gov studies linked to Madrigal Pharmaceuticals EU programs — each row shows trial ID, program name, phase, status, and indication.
Madrigal Pharmaceuticals EU trial registry — 19 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Madrigal Pharmaceuticals EU.
-
MGL-3196-11 — Phase 3
Clinical update -
MGL-3196-19 — Phase 3
Clinical update -
Simvastatin — Phase 1
Clinical update -
Resmetirom — Phase 3
Clinical update -
MGL-3196 (resmetirom) — Phase 2
Clinical update -
Atorvastatin — Phase 1
Clinical update -
100 mg Resmetirom Tablet — Phase 1
Clinical update -
Placebo — Phase 3
Clinical update